FDA Inspection 1260148 — Nicolas Leitz, M.D.
The FDA completed an inspection of Nicolas Leitz, M.D. on Dec 13, 2024 in Stuttgart. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Dec 13, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Stuttgart (Germany)
Additional Details
Clinical Investigator (CI)